| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13213* | 2021 |
| Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition N Jacque, AM Ronchetti, C Larrue, G Meunier, R Birsen, L Willems, ... Blood, The Journal of the American Society of Hematology 126 (11), 1346-1356, 2015 | 379 | 2015 |
| Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia S Park, N Chapuis, J Tamburini, V Bardet, P Cornillet-Lefebvre, L Willems, ... haematologica 95 (5), 819, 2010 | 365 | 2010 |
| The public repository of xenografts enables discovery and randomized phase II-like trials in mice EC Townsend, MA Murakami, A Christodoulou, AL Christie, J Köster, ... Cancer cell 29 (4), 574-586, 2016 | 332 | 2016 |
| Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia L Willems, N Jacque, A Jacquel, N Neveux, T Trovati Maciel, M Lambert, ... Blood, The Journal of the American Society of Hematology 122 (20), 3521-3532, 2013 | 326 | 2013 |
| Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid … J Tamburini, N Chapuis, V Bardet, S Park, P Sujobert, L Willems, N Ifrah, ... Blood, The Journal of the American Society of Hematology 111 (1), 379-382, 2008 | 318 | 2008 |
| PI3K and mTOR signaling pathways in cancer: new data on targeted therapies L Willems, J Tamburini, N Chapuis, C Lacombe, P Mayeux, D Bouscary Current oncology reports 14, 129-138, 2012 | 244 | 2012 |
| The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation AS Green, N Chapuis, T Trovati Maciel, L Willems, M Lambert, C Arnoult, ... Blood, The Journal of the American Society of Hematology 116 (20), 4262-4273, 2010 | 244 | 2010 |
| PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML S Park, N Chapuis, V Bardet, J Tamburini, N Gallay, L Willems, ZA Knight, ... Leukemia 22 (9), 1698-1706, 2008 | 242 | 2008 |
| Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series A Bergeron, D Réa, V Levy, C Picard, V Meignin, J Tamburini, ... American journal of respiratory and critical care medicine 176 (8), 814-818, 2007 | 241 | 2007 |
| Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients S Georgin‐Lavialle, B Terrier, AF Guedon, M Heiblig, T Comont, E Lazaro, ... British Journal of Dermatology 186 (3), 564-574, 2022 | 239 | 2022 |
| Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia J Tamburini, AS Green, V Bardet, N Chapuis, S Park, L Willems, ... Blood, The Journal of the American Society of Hematology 114 (8), 1618-1627, 2009 | 230 | 2009 |
| High levels of CD34+ CD38low/− CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang … F Vergez, AS Green, J Tamburini, JE Sarry, B Gaillard, ... haematologica 96 (12), 1792, 2011 | 215 | 2011 |
| Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia N Chapuis, J Tamburini, AS Green, C Vignon, V Bardet, A Neyret, ... Clinical Cancer Research 16 (22), 5424-5435, 2010 | 208 | 2010 |
| The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia L Willems, N Chapuis, A Puissant, TT Maciel, AS Green, N Jacque, ... Leukemia 26 (6), 1195-1202, 2012 | 183 | 2012 |
| Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients J Tamburini, C Elie, V Bardet, N Chapuis, S Park, P Broët, ... Blood, The Journal of the American Society of Hematology 110 (3), 1025-1028, 2007 | 174 | 2007 |
| Management and outcome of primary CNS lymphoma in the modern era: an LOC network study C Houillier, C Soussain, H Ghesquières, P Soubeyran, O Chinot, ... Neurology 94 (10), e1027-e1039, 2020 | 168 | 2020 |
| Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody N Chapuis, J Tamburini, P Cornillet-Lefebvre, L Gillot, V Bardet, L Willems, ... haematologica 95 (3), 415, 2010 | 158 | 2010 |
| Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies N Chapuis, J Tamburini, AS Green, L Willems, V Bardet, S Park, ... Leukemia 24 (10), 1686-1699, 2010 | 132 | 2010 |
| Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells C Larrue, E Saland, H Boutzen, F Vergez, M David, C Joffre, MA Hospital, ... Blood, The Journal of the American Society of Hematology 127 (7), 882-892, 2016 | 131 | 2016 |
